SCHEDULE 13D/A: CEA Industries Adopts Poison Pill, YZi Labs Responds

CEA Industries Inc. implemented a poison pill and restrictive bylaws, prompting YZi Labs to comply with new disclosure requirements for its board nomination efforts.

Summary

• CEA Industries Inc. adopted a poison pill rights plan and amended its bylaws on December 29, 2025.
• The amended bylaws introduce significant restrictions and procedural hurdles for nominating director candidates and soliciting written consent from stockholders.
• New requirements for soliciting written consents include lengthy and onerous disclosures, a written questionnaire, and a representation and agreement from each proposed director nominee.
• YZi Labs Management Ltd. and Changpeng Zhao each beneficially own 2,150,481 shares, representing 4.9% of CEA Industries Inc. common stock.
• He Jiajin beneficially owns 2,099,644 shares, representing 4.6% of CEA Industries Inc. common stock.
• Alex Odagiu beneficially owns 4,918 shares, representing 0.01% of CEA Industries Inc. common stock.
• On December 29, 2025, YZi Labs delivered a written request to CEA Industries Inc. for the required questionnaire and representation/agreement forms.
• Ms. Ling Zhang, a potential director nominee of YZi Labs, also requested the Issuer's director guidelines and policies to comply with the new bylaws.

Sentiment

Score: 4

Explanation: The filing indicates increased friction and defensive maneuvers by the company against a significant shareholder's efforts to influence governance, introducing uncertainty and procedural challenges for the activist's agenda.

Positives

• YZi Labs is actively pursuing its previously announced solicitation of consents, demonstrating commitment to its strategic objectives despite new hurdles.
• For current management, the adoption of a poison pill and restrictive bylaws strengthens their defense against potential hostile takeovers or significant shareholder influence.

Negatives

• The newly adopted bylaws and poison pill by CEA Industries Inc. create significant procedural hurdles and increased disclosure requirements for YZi Labs' board nomination and consent solicitation efforts.
• The "lengthy and onerous disclosure" requirements may delay YZi Labs' ability to expand the Board and appoint its nominees.

Risks

• The new bylaws and poison pill could lead to a prolonged corporate governance dispute between CEA Industries Inc. and YZi Labs.
• Increased difficulty for shareholder activism may deter other potential investors or activists from engaging with the company.
• The extensive disclosure requirements could increase legal and administrative costs for YZi Labs.

Future Outlook

YZi Labs intends to continue its efforts to expand the Board and appoint its nominees, despite the new and more stringent procedural hurdles imposed by CEA Industries Inc.'s amended bylaws and poison pill.

Management Comments

• CEA Industries Inc. management adopted a poison pill rights plan and amended its bylaws to add significant restrictions and procedural hurdles for nominating director candidates and soliciting stockholder consent.
• YZi Labs management, through its authorized signatory Ling Zhang, delivered a written request to CEA Industries Inc. for the forms required by the new bylaws to proceed with its previously announced consent solicitation.

Industry Context

The adoption of a poison pill and restrictive bylaws by CEA Industries Inc. is a common corporate defense strategy employed by companies to deter hostile takeovers or significant shareholder activism. This action highlights an ongoing trend of companies utilizing governance mechanisms to maintain control against activist investors seeking board representation or strategic changes.

Comparison to Industry Standards

• Poison pills (shareholder rights plans) are a well-established, albeit controversial, corporate defense mechanism used by companies to prevent unwanted takeovers by making the target company's stock prohibitively expensive for an acquirer. While common, they often face scrutiny from institutional investors and proxy advisory firms.
• The implementation of restrictive bylaws, particularly those imposing 'lengthy and onerous disclosure' requirements for director nominations and consent solicitations, is a tactic increasingly used by boards to manage shareholder activism. Such measures can be compared to similar actions taken by companies like D.R. Horton or Papa John's International in past proxy contests, where boards sought to control the nomination process.

Corporate Governance

Stakeholder Impact

• Shareholders, particularly YZi Labs and its affiliates, face increased difficulty and cost in exercising their rights to influence corporate governance and board composition.
• Current management and the board of CEA Industries Inc. gain stronger defensive capabilities against activist investors and potential hostile takeovers.
• Potential director nominees face more stringent disclosure and compliance requirements.

Next Steps

• YZi Labs will proceed with fulfilling the new disclosure requirements, including submitting the requested questionnaires, representations, and agreements for its potential director nominees.
• Ms. Ling Zhang will review the Issuer's director guidelines and policies to ensure compliance for her potential nomination.

Key Dates

Recommendation

The filing details a significant corporate governance dispute, with CEA Industries Inc. implementing strong defensive measures against a major shareholder's efforts to influence the board. This introduces considerable uncertainty regarding the company's future strategic direction and potential for prolonged conflict. While the filing doesn't provide financial performance data, the governance battle itself creates an environment of elevated risk and unpredictability, making a 'hold' position prudent until the outcome of this contest and its implications for shareholder value become clearer.

Keywords

CEA Industries, YZi Labs, Schedule 13D, Poison Pill, Corporate Governance, Shareholder Activism, Board Nomination, Bylaws Amendment, Beneficial Ownership